Healthcare resource utilization in myeloproliferative neoplasms: a population-based study from Ontario, Canada

References

• Yabroff KR, Lund J, Kepka D, et al. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev. 2011;20(10):2006–2014.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Meropol NJ, Schrag D, Smith TJ, et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. JCO. 2009;27(23):3868–3874.
   PubMed Web of Science ®Google Scholar
• Gabriela Dieguez F, Ferro C, Rotter CD. The cost burden of blood cancer care. [Internet]. New York: Leukemia and Lymphoma Society; 2018 [cited November 15, 2019]. 40 p. Available from: www.lls.org/sites/default/files/Milliman%20study%20cost%20burden%20of%20 blood%20cancer%20care.pdf
   Google Scholar
• Burns R, Leal J, Sullivan R, et al. Economic burden of malignant blood disorders across Europe: a population-based cost analysis. Lancet Haematol. 2016;3(8):e362–e70.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Mahmoud D, Kucmin-Bemelmans IT, et al. Economic burden associated with acute myeloid leukemia treatment. Expert Rev Hematol. 2016;9(1):79–89.
   PubMed Web of Science ®Google Scholar
• Foster T, Miller JD, Boye ME, et al. Economic burden of follicular non-Hodgkin’s lymphoma. PharmacoEconomics. 2009;27(8):657–679.
   PubMed Web of Science ®Google Scholar
• Tolley K, Morgan G, Cartwright R, et al. Economic aspects of non-hodgkin's lymphoma [Internet]. London: Office of Health Economics; 1998 [cited December 11, 2019]. 66 p. Available from: https://www.ohe.org/publications/economic-aspects-non-hodgkins-lymphoma
   Google Scholar
• Reis A, Ihle P, Paulus U, et al. Cost of illness of malignant lymphoma in Germany. Eur J Cancer Care. 2006;15(4):379–385.
   PubMed Web of Science ®Google Scholar
• MacEwan JP, Batt K, Yin W, et al. Economic burden of multiple myeloma among patients in successive lines of therapy in the United States. Leukemia Lymphoma. 2018;59(4):941–949.
   PubMed Web of Science ®Google Scholar
• Teitelbaum A, Ba-Mancini A, Huang H, et al. Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data. Oncologist. 2013;18(1):37–45.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Abouzaid S, Bonafede M, et al. Trends in overall survival and costs of multiple myeloma, 2000–2014. Leukemia. 2017;31(9):1915–1921.
   PubMed Web of Science ®Google Scholar
• Kutikova L, Bowman L, Chang S, et al. Medical costs associated with non-Hodgkin’s lymphoma in the United States during the first two years of treatment. Leukemia Lymphoma. 2006;47(8):1535–1544.
   PubMed Web of Science ®Google Scholar
• Mehta J, Wang H, Fryzek JP, et al. Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan. Leukemia Lymphoma. 2014;55(10):2368–2374.
   PubMed Web of Science ®Google Scholar
• Improving the management of care for high-cost medicaid patients. Health Affairs. 2007;26(6):1643–1654.
   Web of Science ®Google Scholar
• Lubitz J, Cai L, Kramarow E, et al. Health, life expectancy, and health care spending among the elderly. N Engl J Med. 2003;349(11):1048–1055.
   PubMed Web of Science ®Google Scholar
• Lehnert T, Heider D, Leicht H, et al. Review: health care utilization and costs of elderly persons with multiple chronic conditions. Med Care Res Rev. 2011;68(4):387–420.
   PubMed Web of Science ®Google Scholar
• Pitchforth E, Russell E, Van der Pol M. Access to specialist cancer care: is it equitable? Br J Cancer. 2002;87(11):1221–1226.
   PubMed Web of Science ®Google Scholar
• Burns LR, Muller RW. Hospital‐physician collaboration: landscape of economic integration and impact on clinical integration. Milbank Quarterly. 2008;86(3):375–434.
   PubMed Web of Science ®Google Scholar
• Schmidt I, Thor J, Davidson T, et al. The national program on standardized cancer care pathways in Sweden: observations and findings half way through. Health Policy. 2018;122(9):945–948.
   PubMed Web of Science ®Google Scholar
• Percy FA, Jack C, Shanmugaratnam A, et al. International classification of diseases for oncology 2000.
   Google Scholar
• Statistics Canada. Postal CodeOM Conversion File (PCCF), Reference Guide [Internet]. Ottawa, ON: Ministry of Industry; 2017 [cited December 11, 2019]. 23 p. Catalogue no. 92–154-G. Available from: https://www.canadapost.ca/cpc/assets/cpc/uploads/files/marketing/2017-postal-code-conversion-file-reference-guide-en.pdf
   Google Scholar
• Austin PC, van Walraven C, Wodchis WP, et al. Using the Johns Hopkins Aggregated Diagnosis Groups (ADGs) to predict mortality in a general adult population cohort in Ontario, Canada. Med Care. 2011;49(10):932–939.
   PubMed Web of Science ®Google Scholar
• Weiner JP, Abrams C, Bodycombe D. The Johns Hopkins ACG case-mix system version 6.0 release notes. Baltimore, MD: Johns Hopkins Bloomberg School of Public Health; 2003.
   Google Scholar
• Wodchis WP, Bushmeneva K, Nikitovic M, et al. Guidelines on Person-Level Costing Using Administrative Databases in Ontario [Internet]. The Health System Performance Research Network; 2013 [cited December 15, 2019]. 70 p. Available from: http://www.sky9games.com/hsprn/uploads/files/Guidelines_on_PersonLevel_Costing_May_2013.pdf
   Google Scholar
• Gregori D, Petrinco M, Bo S, et al. Regression models for analyzing costs and their determinants in health care: an introductory review. Int J Qual Health Care. 2011;23(3):331–341.
   PubMed Web of Science ®Google Scholar
• De Stefano V, for the GIMEMA CMD-Working Party, Za T, Rossi E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica. 2008;93(3):372–380.
   PubMed Web of Science ®Google Scholar
• Elliott MA, Pardanani A, Lasho TL, et al. Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked. Haematologica. 2010;95(10):1788–1791.
   PubMed Web of Science ®Google Scholar
• Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. JMCP. 2007;13(6):475–486.
   PubMed Web of Science ®Google Scholar
• Lefebvre P, Laliberté F, Nutescu EA, et al. All-cause and disease-related health care costs associated with recurrent venous thromboembolism. Thromb Haemost. 2013;110(12):1288–1297.
   PubMedGoogle Scholar
• Scherber RM, Senyak Z, Dueck AC, et al. The impact of medical comorbidities in MPN-related fatigue. Blood. 2014;124(21):1862–1862.
   Web of Science ®Google Scholar
• Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37–43.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Cervantes F, Vannucchi AM, et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood. 2010;116(15):2857–2858.
   PubMed Web of Science ®Google Scholar
• Karantanos T, Chaturvedi S, Spivak JL, et al. Independent association of male sex with presentation and clinical outcomes in myeloproliferative neoplasms. Blood. 2018;132(Supplement 1):1768–1768. 2018;
   Google Scholar
• Vannucchi AM, Harrison CN. Emerging treatments for classical myeloproliferative neoplasms. Blood. 2017;129(6):693–703.
   PubMed Web of Science ®Google Scholar
• Peikes D, Chen A, Schore J, et al. Effects of care coordination on hospitalization, quality of care, and health care expenditures among medicare beneficiaries: 15 randomized trials. JAMA. 2009;301(6):603–618.
   PubMed Web of Science ®Google Scholar
• Austin PC, Walraven C. The mortality risk score and the ADG score: two points-based scoring systems for the Johns Hopkins aggregated diagnosis groups to predict mortality in a general adult population cohort in Ontario, Canada. Med Care. 2011;49(10):940–947.
   PubMed Web of Science ®Google Scholar
• Barber J, Thompson S. Multiple regression of cost data: use of generalised linear models. J Health Serv Res Policy. 2004;9(4):197–204.
   PubMedGoogle Scholar
• Moran JL, Solomon PJ, Peisach AR, et al. New models for old questions: generalized linear models for cost prediction. J Eval Clin Pract. 2007;13(3):381–389.
   PubMed Web of Science ®Google Scholar